Compare · ORKA vs VRAX
ORKA vs VRAX
Side-by-side comparison of Oruka Therapeutics Inc. (ORKA) and Virax Biolabs Group Limited (VRAX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ORKA and VRAX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $6.32B, about 4270.7x VRAX ($1.5M).
- ORKA has been more active in the news (8 items in the past 4 weeks vs 3 for VRAX).
- ORKA has more recent analyst coverage (11 ratings vs 1 for VRAX).
- Company
- Oruka Therapeutics Inc.
- Virax Biolabs Group Limited
- Price
- -
- -
- Market cap
- $6.32B
- $1.5M
- 1M return
- +18.07%
- -
- 1Y return
- +262.72%
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- News (4w)
- 8
- 3
- Recent ratings
- 11
- 1
Virax Biolabs Group Limited
Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company offers rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, and individual consumers. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. The company was incorporated in 2021 and is based in London, the United Kingdom.
Latest ORKA
- Oruka Therapeutics to Participate in Multiple Upcoming Conferences
- Chief Executive Officer Klein Lawrence Otto exercised 25,000 shares at a strike of $7.80 and sold $2,390,125 worth of shares (25,000 units at $95.60) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 8-K filed by Oruka Therapeutics Inc.
- Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis
- Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026
- General Counsel Quinlan Paul T sold $706,735 worth of shares (9,000 units at $78.53) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Medical Officer Goncalves Joana sold $523,648 worth of shares (7,000 units at $74.81) as part of a pre-agreed trading plan (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun sold $805,889 worth of shares (9,999 units at $80.60) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Klein Lawrence Otto exercised 25,000 shares at a strike of $7.80 and sold $2,090,593 worth of shares (25,000 units at $83.62) as part of a pre-agreed trading plan (SEC Form 4)
- Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
Latest VRAX
- SEC Form 6-K filed by Virax Biolabs Group Limited
- Virax Biolabs Appoints Three Distributors for ImmuneSelect Research Products in Mainland China
- SEC Form 3 filed by Virax Biolabs Group Limited
- SEC Form 6-K filed by Virax Biolabs Group Limited
- SEC Form 424B5 filed by Virax Biolabs Group Limited
- SEC Form EFFECT filed by Virax Biolabs Group Limited
- Amendment: SEC Form F-3/A filed by Virax Biolabs Group Limited
- SEC Form 6-K filed by Virax Biolabs Group Limited
- SEC Form 6-K filed by Virax Biolabs Group Limited
- SEC Form 6-K filed by Virax Biolabs Group Limited